Arcellx, Inc.(ACLX) Stock Research - Grey Stern Research
Loading...

Arcellx, Inc. (ACLX) Stock Analysis

$75.82 (-0.54%)

ACLX Financial Performance


Use the table below to view Arcellx, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $76.23 -
52 Week Low $30.88 -
52 Week High $88.66 -
Market Cap $4.1 Billion 2/5
Gross Margin 95% 1/5
Profit Margin -99% 5/5
EBITDA margin -123% 4/5
Q2 - 2024 Revenue $27.4 Million 1/5
Q2 - 2024 Earnings -$27.2 Million 2/5
Q2 - 2024 Free Cash Flow -$39.5 Million 3/5
Trailing 4 Quarters Revenue $144.7 Million 1/5
Trailing 4 Quarters Earnings -$54.2 Million 1/5
Quarterly Earnings Growth -14% 3/5
Annual Earnings Growth 49% 1/5
Quarterly Revenue Growth 91% 1/5
Annual Revenue Growth 113% 1/5
Cash On Hand $100.2 Million 3/5
Short Term Debt $26.4 Million 1/5
Long Term Debt $47.9 Million 1/5

Arcellx, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Arcellx, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/5
PS 28.31 3/5
PB 8.41 2/5
PC 40.88 2/5
Liabilities to Equity 0.51 1/5
ROA -0.07 1/5
ROE -0.11 1/5
Current Ratio 2.97 5/5
Quick Ratio 2.09 5/5
Long Term Debt to Equity 0.10 1/5
Debt to Equity 0.15 1/5
Burn Rate 2.81 3/5
Cash to Cap 0.02 4/5
CCR 1.45 2/5
EV to EBITDA -120.63 5/5
EV to Revenue 28.13 3/5

Company Details

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

CEO:

Website: https://arcellx.com

Address: 25 West Watkins Mill Road Gaithersburg, MD

Exchange: NASDAQ Global Select

Industry: Biotechnology

Arcellx, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Arcellx, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Biomea Fusion, Inc. BMEA $366.8 Million
Nuvalent, Inc. NUVL $7.2 Billion
Day One Biopharmaceuticals, Inc. DAWN $1.2 Billion
Ventyx Biosciences, Inc. VTYX $149.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ACLX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 27.4 Million -$27.2 Million
Q1 2024 $ 39.3 Million -$7.2 Million
Q4 2023 $ 63.1 Million $19.5 Million
Q3 2023 $ 15.0 Million -$39.3 Million
Q2 2023 $ 14.3 Million -$23.9 Million
Q1 2023 $ 17.9 Million -$27.3 Million
Q4 2022 $ 0 -$37.4 Million
Q3 2022 $ 0 -$91.9 Million

View All

ACLX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $100.2 Million $734.3 Million $74.3 Million $487.2 Million
Q1 2024 $154.8 Million $779.7 Million $87.4 Million $496.6 Million
Q4 2023 $0 $337.0 Million $0 $0
Q3 2023 $126.1 Million $614.2 Million $108.7 Million $266.1 Million
Q2 2023 $303.7 Million $623.5 Million $93.6 Million $293.7 Million
Q1 2023 $274.9 Million $622.9 Million $87.6 Million $303.7 Million
Q4 2022 $64.2 Million $313.8 Million $88.1 Million $205.0 Million
Q3 2022 $56.8 Million $337.3 Million $86.9 Million $236.3 Million

View All

ACLX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$39.5 Million -$3.2 Million -$54.5 Million
Q1 2024 -$38.3 Million -$6.4 Million -$241.7 Million
Q4 2023 $53.0 Million -$5.3 Million $267.9 Million
Q3 2023 -$18.0 Million -$7.9 Million -$175.1 Million
Q2 2023 $10.4 Million $0 $10.4 Million
Q1 2023 $181.1 Million -$980,000 $210.7 Million
Q4 2022 -$28.8 Million -$1.3 Million $7.4 Million
Q3 2022 -$17.0 Million -$385,000 -$107.8 Million

View All